{
  "source": "PA-Med-Nec-Fasenra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2175-9\nProgram Prior Authorization/Medical Necessity\nMedications *Fasenra™ (benralizumab)\n*This program applies to the prefilled autoinjector formulation.\nP&T Approval Date 10/2019, 4/2020, 4/2021, 6/2021, 11/2021, 2/2022, 2/2023, 7/2023,\n7/2024\nEffective Date 10/1/2024\n1. Background:\nFasenra (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal\nantibody indicated for the add-on maintenance treatment of patients with severe asthma aged 6\nyears and older, and with an eosinophilic phenotype.\nFasenra is not used for treatment of other eosinophilic conditions or for relief of acute\nbronchospasm or status asthmaticus.\n2. Coverage Criteriaa:\nA. Severe Asthma\n1. Initial Authorization\na. Fasenra will be approved based on one of the following criteria:\n(1) All of the following:\n(a) Patient has been established on therapy with Fasenra under an active\nUnitedHealthcare medical benefit prior authorization for the treatment of\nsevere asthma\n-AND-\n(b) Documentation of positive clinical response to Fasenra therapy as\ndemonstrated by at least one of the following:\ni. Reduction in the frequency of exacerbations\nii. Decreased utilization of rescue medications\niii. Increase in percent predicted FEV1 from pretreatment baseline\niv. Reduction in severity or frequency of asthma-related symptoms\n(e.g., wheezing, shortness of breath, coughing, etc.)\nv. Reduction in oral corticosteroid requirements\n-AND-\n(c) Fasenra is being used in combination with an inhaled corticosteroid (ICS)-\ncontaining maintenance medication [e.g., Advair/AirDuo\n(fluticasone/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol),\n© 2024 UnitedHealthcare Services, Inc.\n1\nSymbicort (budesonide/ formoterol), Trelegy Ellipta (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(d) Patient is not receiving Fasenra in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucal",
    "a (fluticasone\nfuroate/umeclidinium/vilanterol)].\n-AND-\n(d) Patient is not receiving Fasenra in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n(mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(e) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\n-OR-\n(2) All of the following:\n(a) Diagnosis of severe asthma\n-AND-\n(b) Classification of asthma as uncontrolled or inadequately controlled as\ndefined by at least one of the following\ni. Poor symptom control (e.g., Asthma Control Questionnaire [ACQ]\nscore consistently greater than 1.5 or Asthma Control Test [ACT] score\nconsistently less than 20)\nii. Two or more bursts of systemic corticosteroids for at least 3 days each\nin the previous 12 months\niii. Asthma-related emergency treatment (e.g., emergency room visit,\nhospital admission, or unscheduled physician’s office visit for nebulizer\nor other urgent treatment)\niv. Airflow limitation (e.g., after appropriate bronchodilator withhold\nforced expiratory volume in 1 second [FEV1] less than 80% predicted\n[in the face of reduced FEV1/forced vital capacity [FVC] defined as\nless than the lower limit of normal])\nv. Patient is currently dependent on oral corticosteroids for the treatment\nof asthma\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n2\n(c) Submission of medical records (e.g., chart notes, laboratory values, etc.)\nconfirming asthma is an eosinophilic phenotype as defined by a baseline\n(pre-treatment) peripheral blood eosinophil level ≥ 150 cells/μL\n-AND-\n(d) Fasenra will be used in combination with one of the following:\ni. One maximally dosed (appropriately adjusted for age) combination\ninhaled corticosteroid (ICS)/long-acting beta agonist (LABA) [e.g.,\n2\nAdvair/AirDuo Respiclick (fluticasone propionate/salmeterol),\nSymbicort",
    "ximally dosed (appropriately adjusted for age) combination\ninhaled corticosteroid (ICS)/long-acting beta agonist (LABA) [e.g.,\n2\nAdvair/AirDuo Respiclick (fluticasone propionate/salmeterol),\nSymbicort (budesonide/formoterol), Breo Ellipta (fluticasone\nfuroate/vilanterol)]\n-OR-\nii. Combination therapy including both of the following:\n• One maximally dosed (appropriately adjusted for age) ICS\nproduct [e.g., ciclesonide (Alvesco), mometasone furoate\n(Asmanex), beclomethasone dipropionate (QVAR)]\n-AND-\n• One additional asthma controller medication [e.g., LABA -\nolodaterol (Striverdi) or indacaterol (Arcapta); leukotriene\nreceptor antagonist – montelukast (Singulair); theophylline]\n-AND-\n(e) Patient is not receiving Fasenra in combination with any of the following:\ni. Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n(mepolizumab)]\nii. Anti-IgE therapy [e.g., Xolair (omalizumab)]\niii. Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\niv. Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\n-AND-\n(f) Prescribed by one of the following:\ni. Allergist\nii. Immunologist\niii. Pulmonologist\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n3\n2. Reauthorization\na. Fasenra will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Fasenra therapy as demonstrated\nby at least one of the following:\n(a) Reduction in the frequency of exacerbations\n(b) Decreased utilization of rescue medications\n(c) Increase in percent predicted FEV1 from pretreatment baseline\n(d) Reduction in severity or frequency of asthma-related symptoms (e.g.,\nwheezing, shortness of breath, coughing, etc.)\n(e) Reduction in oral corticosteroid requirements\n-AND-\n(2) Fasenra is being used in combination with an ICS-containing maintenance\nmedication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta\n(fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy\nEllipta (",
    "nation with an ICS-containing maintenance\nmedication [e.g., Advair/AirDuo (fluticasone/salmeterol), Breo Ellipta\n(fluticasone furoate/vilanterol), Symbicort (budesonide/ formoterol), Trelegy\nEllipta (fluticasone furoate/umeclidinium/vilanterol)].\n-AND-\n(3) Patient is not receiving Fasenra in combination with any of the following:\n(a) Anti-interleukin 5 therapy [e.g., Cinqair (resilizumab), Nucala\n(mepolizumab)]\n(b) Anti-IgE therapy [e.g., Xolair (omalizumab)]\n(c) Anti-interleukin 4 therapy [e.g., Dupixent (dupilumab)]\n(d) Thymic stromal lymphopoietin (TSLP) inhibitor [e.g., Tezspire\n(tezepelumab)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limitations may be in place.\n• Medical Necessity may be in place.\n• The prefilled syringe is typically covered under the medical benefit. Please refer to the United\nHealthcare Medical Benefit Drug Policy: “Respiratory Interleukins (Cinqair®, Fasenra®, and\nNucala®)”.\n© 2024 UnitedHealthcare Services, Inc.\n4\n4. References:\n1. Fasenra [prescribing information]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; February\n2021.\n2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition,\nevaluation and treatment of severe asthma. Eur Respir J. 2014 Feb:43(2):343-73.\n3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023.\nAvailable at http://www.ginasthma.org. Accessed June 8, 2023.\n4. Centers for Disease Control and Prevention. Asthma. Available a",
    "for Asthma. Global Strategy for Asthma Management and Prevention, 2023.\nAvailable at http://www.ginasthma.org. Accessed June 8, 2023.\n4. Centers for Disease Control and Prevention. Asthma. Available at http://www.cdc.gov. Accessed\nDecember 2022.\n5. National Heart, Lung and Blood Institute. Asthma Management Guidelines. Available at\nhttp://www.nhlbi.nih.gov. Accessed December 2022.\n6. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with\nbenralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA\nstudies. Lancet Respir Med. 2017 Sep 8.\n7. Goldman M, Hirsch I, Zangrilli JG, et al. The association between blood eosinophil count and\nbenralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III\nSIROCCO and CALIMA studies. Curr Med Res Opin. 2017 Sep;33(9):1605-1613.\n8. Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L,\nKhurana S, Knight S, McDonald VM, Morgan RL, Ortega VE, Rigau D, Subbarao P, Tonia T,\nAdcock IM, Bleecker ER, Brightling C, Boulet LP, Cabana M, Castro M, Chanez P, Custovic A,\nDjukanovic R, Frey U, Frankemölle B, Gibson P, Hamerlijnck D, Jarjour N, Konno S, Shen H,\nVitary C, Bush A. Management of severe asthma: a European Respiratory Society/American\nThoracic Society guideline. Eur Respir J. 2020 Jan 2;55(1):1900588. doi:\n10.1183/13993003.00588-2019. PMID: 31558662\nProgram Prior Authorization/Notification - Fasenra (benralizumab)\nChange Control\n10/2019 New program.\n4/2020 Updated program to address specific product formulations. Updated\nreferences.\n4/2021 Annual review. No changes to clinical criteria. Added limitations of\nuse. Updated references.\n6/2021 Added criteria if patient has been approved and received initial dose of\nFasenra directly monitored by a healthcare professional without\nreaction.\n11/2021 Added coverage criteria for patients established on therapy under\nUnitedHealthcare medical benefit. Removed prescri",
    "of\nFasenra directly monitored by a healthcare professional without\nreaction.\n11/2021 Added coverage criteria for patients established on therapy under\nUnitedHealthcare medical benefit. Removed prescriber requirement for\nreauthorization.\n2/2022 Added Tezspire to list of agents not to be used in combination with\nFasenra and updated formatting of prescriber requirement.\n2/2023 Annual review with no updates to coverage criteria. Updated\nreferences.\n7/2023 Updated coverage criteria for severe asthma to align with GINA &\nERS/ATS guidelines. Added/updated examples of ICS-containing\nmaintenance medications, removed requirement that peripheral blood\neosinophil level must be within 6 weeks, and removed bypass of\n© 2024 UnitedHealthcare Services, Inc.\n5\neosinophilic phenotype requirement for patients currently dependent on\nmaintenance therapy with oral corticosteroids. Updated references.\n7/2024 Annual review. Modified criteria for existing prior authorization for\nunder the medical benefit. Updated background for expanded indication\nfor ages 6 years and older. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n6"
  ]
}